# A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct04669171/  
OnCo record `nct04669171` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenalidomide, Rituximab in follicular lymphoma, run by Enterome, now recruiting.

## Summary

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT04669171 by Enterome, with 80 participants planned, started 2021-07-05 and due to reach its primary completion in 2029-05-30. Interventions recorded: EO2463, lenalidomide, rituximab. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04669171
- Phase: 1/2
- Setting: A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma
- Sponsor: Enterome
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT04669171: https://clinicaltrials.gov/study/NCT04669171

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct04669171.json